Kura rises on $30 mln milestone payment after first patient dosed in late-stage trial

Kura Oncology

24/10/2025 12:43

** Shares of drugmaker Kura Oncology KURA.O rise 5.6% to $9.61 premarket

** Co gets $30 mln milestone payment after dosing first patient in a late-stage trial for acute myeloid leukemia (AML), a fast-growing blood cancer

** The trial tests oral experimental drug ziftomenib plus chemo in newly diagnosed AML patients with NPM1 or KMT2A mutations - KURA

** The mutations are genetic changes found in AML; NPM1 is linked to better initial chemo response, while KMT2A is tied to aggressive disease and higher relapse risk

** Trial launch announced last month; ziftomenib is a once-daily oral treatment, co says

** The disease affects about 22,000 people in the US every year, according to American Cancer Society

** Up to last close, stock up ~4% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))